CVS Health's Specialty revenues rose roughly 53% in the second quarter of 2014 on the back of drug price inflation, utilization, new product launches and new client wins. Moving forward, management expects drug price inflation, new product launch, higher utilization and new PBM clients to fuel growth. The article sheds light on factors that drive up costs which includes the increasing complexity and effectiveness of new medications; changing dynamics of target populations that broaden the patient population eligible for treatment; and how and where specialty medications are delivered.